Hereditary Angioedema (HAE) Therapeutics Market End-user, Product, and Geography - Forecast and Analysis 2023-2027

Published: Oct 2023 Pages: 156 SKU: IRTNTR75935

Hereditary Angioedema (HAE) Therapeutics Market Forecast 2023-2027

The hereditary angioedema (HAE) therapeutics market size is estimated to grow by USD 1.65 billion at a CAGR of 8.95% between 2022 and 2027. 

One of the factors contributing to the rise in hereditary angioedema prevalence is improved awareness and diagnosis. In the past, hereditary angioedema was frequently misdiagnosed or undiagnosed altogether, leading to an underestimation of its prevalence. More cases of hereditary Angioedema are being recognized and reported due to increased awareness among healthcare professionals and improved diagnostic tools. Furthermore, its increased incidence was also due to a more intensive study and a further understanding of hematological angioedema. As scientists and healthcare professionals gain a better understanding of the genetic basis and primary mechanisms of hereditary angioedema, they are able to identify more individuals with the condition. This increased knowledge has also led to better education and awareness among the general population, prompting individuals with symptoms of hereditary angioedema to seek medical attention and receive an accurate diagnosis. Such factors will increase the market growth during the forecast period. 

What will be the size of the Market During the Forecast Period?

To learn more about this report, Request Free Sample

Market Segmentation

The market focuses on addressing symptoms like edema in hands and feet caused by deficiencies in the C1 esterase inhibitor (C1-INH). Therapeutic interventions target blood vessels and involve treatments such as synthesis of inhibitor and managing spontaneous mutation in the C1 inhibitor gene. Various medications fall under the drug class, and they are made accessible through distribution channel like retail pharmacy to ensure widespread availability and access to treatment options.

Technavio has segmented the market by the End-user segment is classified into hospital pharmacies, retail pharmacies, and e-commerce. The product segment is classified into C1-esterase inhibitor, bradykinin B2 receptor antagonist, kallikrein inhibitor, and others. Also, the geography segment includes key regions such as North America, Europe, Asia, and the Rest of the World (ROW)

By End-user

The market share by the hospital pharmacies segment will be significant during the forecast period. Hospital pharmacies play a crucial role in the hereditary angioedema (HAE) therapeutics market. Hospital pharmacies are becoming pivotal in providing the necessary medicines and treatments for patients with hereditary angioedema, due to the rise in prevalence of hereditary angioedema.

Get a glance at the market contribution of various segments View a PDF Sample

The hospital pharmacies segment was valued at USD 991.73 million in 2017. Hospital pharmacies must actively engage in sourcing these medications from reliable suppliers to ensure they have sufficient stock to meet the demands of hereditary angioedema patients. Moreover, hospital pharmacies play a key role in dispensing these medications to hereditary angioedema patients. They have direct interaction with patients and their healthcare providers so they can ensure prescriptions, as well as provide necessary guidance for the use of medication.

By Product

C1-esterase inhibitors are a key component in the market. These inhibitors are crucial in managing and treating this rare genetic disorder by preventing attacks of angioedema. C1 Inhibitors work by inhibiting the C1 protein in the complement system, which is part of the immune system in the human body.  The complement system is a major component of the immune system, but in people with hereditary angioedema, it begins to be activated and may result in episodes of severe swelling across all parts of the body, including the face, hand, foot, or gastrointestinal tract. The C1 Inhibitors segment of the hereditary angioedema (HAE) therapeutics market has been growing rapidly in recent years. Increased realization and diagnosis of hereditary angioedema, along with the development of new and improved C1 Inhibitor therapies, have contributed to this growth. Thus, it is expected to increase the demand for C1 Inhibitors among patients with hereditary angioedema, which will drive the growth of the market.

By Region

For more insights about the market share of various regions View PDF Sample now!

North America is estimated to contribute 38% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. North America holds a significant position in the global hereditary angioedema (HAE) therapeutics market. Hereditary angioedema is a rare genetic disorder characterized by recurring episodes of swelling in different parts of the body, including the hands, feet, face, and airways. The region plays a major role in the market due to its strong medical infrastructure, considerable R&D efforts, and large prevalence of hereditary angioedema.

North America provides world-class medical facilities and has a well-developed pharmaceutical industry. This enables advanced diagnostic capabilities, improved treatment options, and the effective management of the disease for patients with hereditary angioedema. Innovation and advancement of treatment options are being encouraged by the large research and development activities in North America related to therapies for hematological angioedema. Numerous pharmaceutical companies in the region are actively involved in developing novel drugs and therapies to address the specific needs of patients with such issues. Such factors will increase the market growth in this region during the forecast period.

Buy Now Full Report and Discover More

Market Dynamics and Customer Landscape

The market addresses conditions like Type I HAE, Type II HAE, and Type III HAE, characterized by edema due to C1 esterase inhibitor (C1-INH) deficiency. Treatment involves managing symptoms and preventing attacks through therapy, including donidalorsen and Kallikrein inhibitors. Physicians, including dermatologists, gastroenterologists, and clinical allergists, play pivotal roles. With options like oral medications and prophylaxis, patients seek relief through various distribution channels, including retail pharmacies. Treatment decisions often consider family history and dysfunctional protein synthesis to tailor therapeutic approaches. There are multiple factors influencing market growth. Our researchers analyzed the data with 2022 as the base year, along with the key trends and challenges. 

Significant Market Trends

The growing demand for personalized medicine is a key trend in the market. The increasing prevalence of hereditary angioedema and the need for more effectual and targeted treatments support the market. Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of swelling in various parts of the body. These episodes may have unpredictable and debilitating effects on the patient, causing significant pain, discomfort, or functional impairment. Traditionally, the treatment options have been limited, with most focusing on managing the symptoms and preventing severe attacks.

However, advancements in personalized medicine have opened up new possibilities for the treatment of hereditary angioedema.  Personalized medicine can lead to a more targeted approach to treatment and the reduction of frequency and severity of attacks, as far as hematological angioedema is concerned. Thus, these factors are expected to increase the demand for personalized medicine, which will drive the growth of the market during the forecast period.

Major Market Challenges

The high cost associated with the development and production is a major challenge in the market growth. The market has seen exceptional development in recent years, with new treatments offering hope to patients diagnosed with this rare genetic disorder. In order to guarantee the safety and efficacy of new therapeutic products for hereditary angioedema, a large amount of research and clinical trials are needed. These processes involve substantial capital investments, which are then reflected in the final cost of the product. 

Additionally, the cost of conducting multiple parts of clinical trials, which range from initial safety assessments to large-scale efficacy studies, can be substantial. Marketing efforts are required to educate healthcare professionals and patients about the therapeutics, while distribution costs are incurred on ensuring that the products reach the target population. Furthermore, in order to monitor the safety and efficacy of therapeutic products once they have been placed on the market, post-marketing surveillance is essential. Thus, such factors are expected to hinder the growth of the market focus during the forecast period.

Buy Now Full Report and Discover More

Market Customer Landscape

The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market forecasting report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Market Customer Landscape

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 16 market companies, including:

Adverum Biotechnologies Inc. - The company initiated preclinical treatment of ADVM 053, which has been approved by the FDA and ODD ADVM 053.

  • Arrowhead Pharmaceuticals Inc.
  • Attune Pharmaceuticals Inc.
  • BioCryst Pharmaceuticals Inc.
  • BioMarin Pharmaceutical Inc.
  • CENTOGENE NV
  • Cipla Ltd.
  • CSL Ltd.
  • Diapharma Group Inc.
  • Intellia Therapeutics Inc.
  • Ionis Pharmaceuticals Inc.
  • KalVista Pharmaceuticals Inc.
  • Pharming Group NV
  • Pharvaris NV
  • Sanofi
  • Takeda Pharmaceutical Co. Ltd.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Segment Overview

The market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027. 

  • End-user Outlook 
    • Hospital pharmacies
    • Retail pharmacies
    • E-commerce
  • Product Outlook 
    • C1-esterase inhibitor
    • Bradykinin B2 receptor antagonist
    • Kallikrein inhibitor
    • Others
  • Region Outlook 
    • North America
      • The U.S.
      • Canada
    • Europe
      • The U.K.
      • Germany
      • France
      • Rest of Europe
    • Asia
      • China
      • India
    • ROW (Rest of the World)
      • Argentina
      • Brazil
      • Australia 

Market Analyst Overview:

The market addresses the critical needs of patients experiencing angioedema attack, offering treatments to alleviate symptoms and improve quality of life. Despite challenges like misdiagnosis and allergic reaction, advancements in intravenous and subcutaneous therapies such as Cinryze, Kalbitor, and Firazyr have transformed care. Emerging options like Orladeyo and Takhzyro, including B2 bradykinin receptor antagonists and tranexamic acid, provide promising alternatives. With a focus on market player and pipeline medications, the industry aims to address the unmet needs of those affected by rare diseases through innovative subcutaneous injections and monoclonal antibodies like lanadelumab.

Further, the market addresses the urgent needs of patients with HAE by offering a range of treatments to manage symptoms and improve quality of life. Despite challenges such as allergic reactions and the risk of appendicitis, patients have access to various options, including SAJAZIR Injection, Ruconest, Icatibant, and Berinert, which provide relief during angioedema attacks. Emerging therapies like Haegarda and attenuated androgens offer promising alternatives alongside intravenous treatments and ACE inhibitors. Market players in the rare illnesses industry continue to innovate to address unmet needs in HAE treatment, including those associated with irritable bowel syndrome (IBS) and allergies.

Market Scope

Report Coverage

Details

Page number

156

Base year

2022

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 8.95%

Market growth 2023-2027

USD 1.65 billion

Market structure

Fragmented

YoY growth 2022-2023(%)

8.81

Regional analysis

North America, Europe, Asia, and the Rest of the World (ROW)

Performing market contribution

North America at 38%

Key countries

US, Canada, Germany, China, and India

Competitive landscape

 Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

Key companies profiled

Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Attune Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., CENTOGENE NV, Cipla Ltd., CSL Ltd., Diapharma Group Inc., Intellia Therapeutics Inc., Ionis Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Pharming Group NV, Pharvaris NV, Sanofi, and Takeda Pharmaceutical Co. Ltd.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

View Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

  • CAGR of the market during the forecast period
  • Detailed information on factors that will drive the market growth and forecasting of the market between 2023 and 2027
  • Precise estimation of the market size and its contribution to the parent market
  • Accurate predictions about upcoming market trends and analysis and changes in consumer behavior
  • Growth of the market across Europe, North America, APAC, South America, and Middle East and Africa
  • Thorough market growth analysis of the market’s competitive landscape and detailed information about companies
  • Comprehensive market analysis and report on the factors that will challenge the market research and growth of market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch

1 Executive Summary

  • 1.1 Market overview
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by End-user
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Product
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
    • 3.4 Market outlook: Forecast for 2022-2027
      • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
      • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
      • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

    4 Historic Market Size

    • 4.1 Global hereditary angioedema therapeutics market 2017 - 2021
      • Exhibit 18: Historic Market Size – Data Table on global hereditary angioedema therapeutics market 2017 - 2021 ($ million)
    • 4.2 End-User Segment Analysis 2017 - 2021
      • Exhibit 19: Historic Market Size – End-User Segment 2017 - 2021 ($ million)
    • 4.3 Product Segment Analysis 2017 - 2021
      • Exhibit 20: Historic Market Size – Product Segment 2017 - 2021 ($ million)
    • 4.4 Geography Segment Analysis 2017 - 2021
      • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
    • 4.5 Country Segment Analysis 2017 - 2021
      • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

    5 Five Forces Analysis

    • 5.1 Five forces summary
      • Exhibit 23: Five forces analysis - Comparison between 2022 and 2027
    • 5.2 Bargaining power of buyers
      • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
    • 5.3 Bargaining power of suppliers
      • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
    • 5.4 Threat of new entrants
      • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
    • 5.5 Threat of substitutes
      • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
    • 5.6 Threat of rivalry
      • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
    • 5.7 Market condition
      • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

    6 Market Segmentation by End-user

    • 6.1 Market segments
      • Exhibit 30: Chart on End-user - Market share 2022-2027 (%)
      • Exhibit 31: Data Table on End-user - Market share 2022-2027 (%)
    • 6.2 Comparison by End-user
      • Exhibit 32: Chart on Comparison by End-user
      • Exhibit 33: Data Table on Comparison by End-user
    • 6.3 Hospital pharmacies - Market size and forecast 2022-2027
      • Exhibit 34: Chart on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 35: Data Table on Hospital pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 36: Chart on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
      • Exhibit 37: Data Table on Hospital pharmacies - Year-over-year growth 2022-2027 (%)
    • 6.4 Retail pharmacies - Market size and forecast 2022-2027
      • Exhibit 38: Chart on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 39: Data Table on Retail pharmacies - Market size and forecast 2022-2027 ($ million)
      • Exhibit 40: Chart on Retail pharmacies - Year-over-year growth 2022-2027 (%)
      • Exhibit 41: Data Table on Retail pharmacies - Year-over-year growth 2022-2027 (%)
    • 6.5 E-commerce - Market size and forecast 2022-2027
      • Exhibit 42: Chart on E-commerce - Market size and forecast 2022-2027 ($ million)
      • Exhibit 43: Data Table on E-commerce - Market size and forecast 2022-2027 ($ million)
      • Exhibit 44: Chart on E-commerce - Year-over-year growth 2022-2027 (%)
      • Exhibit 45: Data Table on E-commerce - Year-over-year growth 2022-2027 (%)
    • 6.6 Market opportunity by End-user
      • Exhibit 46: Market opportunity by End-user ($ million)
      • Exhibit 47: Data Table on Market opportunity by End-user ($ million)

    7 Market Segmentation by Product

    • 7.1 Market segments
      • Exhibit 48: Chart on Product - Market share 2022-2027 (%)
      • Exhibit 49: Data Table on Product - Market share 2022-2027 (%)
    • 7.2 Comparison by Product
      • Exhibit 50: Chart on Comparison by Product
      • Exhibit 51: Data Table on Comparison by Product
    • 7.3 C1-esterase inhibitor - Market size and forecast 2022-2027
      • Exhibit 52: Chart on C1-esterase inhibitor - Market size and forecast 2022-2027 ($ million)
      • Exhibit 53: Data Table on C1-esterase inhibitor - Market size and forecast 2022-2027 ($ million)
      • Exhibit 54: Chart on C1-esterase inhibitor - Year-over-year growth 2022-2027 (%)
      • Exhibit 55: Data Table on C1-esterase inhibitor - Year-over-year growth 2022-2027 (%)
    • 7.4 Bradykinin B2 receptor antagonist - Market size and forecast 2022-2027
      • Exhibit 56: Chart on Bradykinin B2 receptor antagonist - Market size and forecast 2022-2027 ($ million)
      • Exhibit 57: Data Table on Bradykinin B2 receptor antagonist - Market size and forecast 2022-2027 ($ million)
      • Exhibit 58: Chart on Bradykinin B2 receptor antagonist - Year-over-year growth 2022-2027 (%)
      • Exhibit 59: Data Table on Bradykinin B2 receptor antagonist - Year-over-year growth 2022-2027 (%)
    • 7.5 Kallikrein inhibitor - Market size and forecast 2022-2027
      • Exhibit 60: Chart on Kallikrein inhibitor - Market size and forecast 2022-2027 ($ million)
      • Exhibit 61: Data Table on Kallikrein inhibitor - Market size and forecast 2022-2027 ($ million)
      • Exhibit 62: Chart on Kallikrein inhibitor - Year-over-year growth 2022-2027 (%)
      • Exhibit 63: Data Table on Kallikrein inhibitor - Year-over-year growth 2022-2027 (%)
    • 7.6 Others - Market size and forecast 2022-2027
      • Exhibit 64: Chart on Others - Market size and forecast 2022-2027 ($ million)
      • Exhibit 65: Data Table on Others - Market size and forecast 2022-2027 ($ million)
      • Exhibit 66: Chart on Others - Year-over-year growth 2022-2027 (%)
      • Exhibit 67: Data Table on Others - Year-over-year growth 2022-2027 (%)
    • 7.7 Market opportunity by Product
      • Exhibit 68: Market opportunity by Product ($ million)
      • Exhibit 69: Data Table on Market opportunity by Product ($ million)

    8 Customer Landscape

    • 8.1 Customer landscape overview
      • Exhibit 70: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

    9 Geographic Landscape

    • 9.1 Geographic segmentation
      • Exhibit 71: Chart on Market share by geography 2022-2027 (%)
      • Exhibit 72: Data Table on Market share by geography 2022-2027 (%)
    • 9.2 Geographic comparison
      • Exhibit 73: Chart on Geographic comparison
      • Exhibit 74: Data Table on Geographic comparison
    • 9.3 North America - Market size and forecast 2022-2027
      • Exhibit 75: Chart on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 76: Data Table on North America - Market size and forecast 2022-2027 ($ million)
      • Exhibit 77: Chart on North America - Year-over-year growth 2022-2027 (%)
      • Exhibit 78: Data Table on North America - Year-over-year growth 2022-2027 (%)
    • 9.4 Europe - Market size and forecast 2022-2027
      • Exhibit 79: Chart on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 80: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
      • Exhibit 81: Chart on Europe - Year-over-year growth 2022-2027 (%)
      • Exhibit 82: Data Table on Europe - Year-over-year growth 2022-2027 (%)
    • 9.5 Asia - Market size and forecast 2022-2027
      • Exhibit 83: Chart on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 84: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
      • Exhibit 85: Chart on Asia - Year-over-year growth 2022-2027 (%)
      • Exhibit 86: Data Table on Asia - Year-over-year growth 2022-2027 (%)
    • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
      • Exhibit 87: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 88: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
      • Exhibit 89: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
      • Exhibit 90: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • 9.7 US - Market size and forecast 2022-2027
      • Exhibit 91: Chart on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 92: Data Table on US - Market size and forecast 2022-2027 ($ million)
      • Exhibit 93: Chart on US - Year-over-year growth 2022-2027 (%)
      • Exhibit 94: Data Table on US - Year-over-year growth 2022-2027 (%)
    • 9.8 China - Market size and forecast 2022-2027
      • Exhibit 95: Chart on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 96: Data Table on China - Market size and forecast 2022-2027 ($ million)
      • Exhibit 97: Chart on China - Year-over-year growth 2022-2027 (%)
      • Exhibit 98: Data Table on China - Year-over-year growth 2022-2027 (%)
    • 9.9 Germany - Market size and forecast 2022-2027
      • Exhibit 99: Chart on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 100: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
      • Exhibit 101: Chart on Germany - Year-over-year growth 2022-2027 (%)
      • Exhibit 102: Data Table on Germany - Year-over-year growth 2022-2027 (%)
    • 9.10 Canada - Market size and forecast 2022-2027
      • Exhibit 103: Chart on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 104: Data Table on Canada - Market size and forecast 2022-2027 ($ million)
      • Exhibit 105: Chart on Canada - Year-over-year growth 2022-2027 (%)
      • Exhibit 106: Data Table on Canada - Year-over-year growth 2022-2027 (%)
    • 9.11 India - Market size and forecast 2022-2027
      • Exhibit 107: Chart on India - Market size and forecast 2022-2027 ($ million)
      • Exhibit 108: Data Table on India - Market size and forecast 2022-2027 ($ million)
      • Exhibit 109: Chart on India - Year-over-year growth 2022-2027 (%)
      • Exhibit 110: Data Table on India - Year-over-year growth 2022-2027 (%)
    • 9.12 Market opportunity by geography
      • Exhibit 111: Market opportunity by geography ($ million)
      • Exhibit 112: Data Tables on Market opportunity by geography ($ million)

    10 Drivers, Challenges, and Trends

    • 10.1 Market drivers
      • 10.2 Market challenges
        • 10.3 Impact of drivers and challenges
          • Exhibit 113: Impact of drivers and challenges in 2022 and 2027
        • 10.4 Market trends

          11 Vendor Landscape

          • 11.1 Overview
            • 11.2 Vendor landscape
              • Exhibit 114: Overview on Criticality of inputs and Factors of differentiation
            • 11.3 Landscape disruption
              • Exhibit 115: Overview on factors of disruption
            • 11.4 Industry risks
              • Exhibit 116: Impact of key risks on business

            12 Vendor Analysis

            • 12.1 Vendors covered
              • Exhibit 117: Vendors covered
            • 12.2 Market positioning of vendors
              • Exhibit 118: Matrix on vendor position and classification
            • 12.3 Adverum Biotechnologies Inc.
              • Exhibit 119: Adverum Biotechnologies Inc. - Overview
              • Exhibit 120: Adverum Biotechnologies Inc. - Product / Service
              • Exhibit 121: Adverum Biotechnologies Inc. - Key offerings
            • 12.4 Arrowhead Pharmaceuticals Inc.
              • Exhibit 122: Arrowhead Pharmaceuticals Inc. - Overview
              • Exhibit 123: Arrowhead Pharmaceuticals Inc. - Business segments
              • Exhibit 124: Arrowhead Pharmaceuticals Inc. - Key offerings
              • Exhibit 125: Arrowhead Pharmaceuticals Inc. - Segment focus
            • 12.5 Attune Pharmaceuticals Inc.
              • Exhibit 126: Attune Pharmaceuticals Inc. - Overview
              • Exhibit 127: Attune Pharmaceuticals Inc. - Product / Service
              • Exhibit 128: Attune Pharmaceuticals Inc. - Key offerings
            • 12.6 BioCryst Pharmaceuticals Inc.
              • Exhibit 129: BioCryst Pharmaceuticals Inc. - Overview
              • Exhibit 130: BioCryst Pharmaceuticals Inc. - Product / Service
              • Exhibit 131: BioCryst Pharmaceuticals Inc. - Key offerings
            • 12.7 BioMarin Pharmaceutical Inc.
              • Exhibit 132: BioMarin Pharmaceutical Inc. - Overview
              • Exhibit 133: BioMarin Pharmaceutical Inc. - Product / Service
              • Exhibit 134: BioMarin Pharmaceutical Inc. - Key offerings
            • 12.8 CENTOGENE NV
              • Exhibit 135: CENTOGENE NV - Overview
              • Exhibit 136: CENTOGENE NV - Product / Service
              • Exhibit 137: CENTOGENE NV - Key offerings
            • 12.9 Cipla Ltd.
              • Exhibit 138: Cipla Ltd. - Overview
              • Exhibit 139: Cipla Ltd. - Business segments
              • Exhibit 140: Cipla Ltd. - Key news
              • Exhibit 141: Cipla Ltd. - Key offerings
              • Exhibit 142: Cipla Ltd. - Segment focus
            • 12.10 CSL Ltd.
              • Exhibit 143: CSL Ltd. - Overview
              • Exhibit 144: CSL Ltd. - Business segments
              • Exhibit 145: CSL Ltd. - Key news
              • Exhibit 146: CSL Ltd. - Key offerings
              • Exhibit 147: CSL Ltd. - Segment focus
            • 12.11 Intellia Therapeutics Inc.
              • Exhibit 148: Intellia Therapeutics Inc. - Overview
              • Exhibit 149: Intellia Therapeutics Inc. - Business segments
              • Exhibit 150: Intellia Therapeutics Inc. - Key offerings
              • Exhibit 151: Intellia Therapeutics Inc. - Segment focus
            • 12.12 Ionis Pharmaceuticals Inc.
              • Exhibit 152: Ionis Pharmaceuticals Inc. - Overview
              • Exhibit 153: Ionis Pharmaceuticals Inc. - Business segments
              • Exhibit 154: Ionis Pharmaceuticals Inc. - Key news
              • Exhibit 155: Ionis Pharmaceuticals Inc. - Key offerings
              • Exhibit 156: Ionis Pharmaceuticals Inc. - Segment focus
            • 12.13 KalVista Pharmaceuticals Inc.
              • Exhibit 157: KalVista Pharmaceuticals Inc. - Overview
              • Exhibit 158: KalVista Pharmaceuticals Inc. - Product / Service
              • Exhibit 159: KalVista Pharmaceuticals Inc. - Key offerings
            • 12.14 Pharming Group NV
              • Exhibit 160: Pharming Group NV - Overview
              • Exhibit 161: Pharming Group NV - Business segments
              • Exhibit 162: Pharming Group NV - Key offerings
              • Exhibit 163: Pharming Group NV - Segment focus
            • 12.15 Pharvaris NV
              • Exhibit 164: Pharvaris NV - Overview
              • Exhibit 165: Pharvaris NV - Product / Service
              • Exhibit 166: Pharvaris NV - Key offerings
            • 12.16 Sanofi
              • Exhibit 167: Sanofi - Overview
              • Exhibit 168: Sanofi - Business segments
              • Exhibit 169: Sanofi - Key news
              • Exhibit 170: Sanofi - Key offerings
              • Exhibit 171: Sanofi - Segment focus
            • 12.17 Takeda Pharmaceutical Co. Ltd.
              • Exhibit 172: Takeda Pharmaceutical Co. Ltd. - Overview
              • Exhibit 173: Takeda Pharmaceutical Co. Ltd. - Product / Service
              • Exhibit 174: Takeda Pharmaceutical Co. Ltd. - Key news
              • Exhibit 175: Takeda Pharmaceutical Co. Ltd. - Key offerings

            13 Appendix

            • 13.1 Scope of the report
              • 13.2 Inclusions and exclusions checklist
                • Exhibit 176: Inclusions checklist
                • Exhibit 177: Exclusions checklist
              • 13.3 Currency conversion rates for US$
                • Exhibit 178: Currency conversion rates for US$
              • 13.4 Research methodology
                • Exhibit 179: Research methodology
                • Exhibit 180: Validation techniques employed for market sizing
                • Exhibit 181: Information sources
              • 13.5 List of abbreviations
                • Exhibit 182: List of abbreviations

              Research Framework

              Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.

              INFORMATION SOURCES

              Primary sources

              • Manufacturers and suppliers
              • Channel partners
              • Industry experts
              • Strategic decision makers

              Secondary sources

              • Industry journals and periodicals
              • Government data
              • Financial reports of key industry players
              • Historical data
              • Press releases

              DATA ANALYSIS

              Data Synthesis

              • Collation of data
              • Estimation of key figures
              • Analysis of derived insights

              Data Validation

              • Triangulation with data models
              • Reference against proprietary databases
              • Corroboration with industry experts

              REPORT WRITING

              Qualitative

              • Market drivers
              • Market challenges
              • Market trends
              • Five forces analysis

              Quantitative

              • Market size and forecast
              • Market segmentation
              • Geographical insights
              • Competitive landscape

              PURCHASE FULL REPORT OF

              hereditary angioedema therapeutics market

              QUICK BUY

              Key Questions Answered

              • What are the key global market and the regional market share?
              • What are the revenue-generating key market segments?
              • What are the key factors driving and challenging this market’s growth?
              • Who are the key market vendors and their growth strategies?
              • What are the latest trends influencing the growth of this market?
              • What are the variables influencing the market growth in the primary regions?
              • What are the factors influencing the growth of the parent market?

              Why should you prefer Technavio's market insights report?

              • Off-the-shelf research reports
              • Reports can be tailored to meet the customer's needs
              • Trusted by more than 100 fortune 500 organizations
              • Information about the market's key drivers, trends, and challenges
              • Parent market analysis
              • Every week, 50,000 people visit our subscription platform
              • Detailed vendors report with competitive landscape
              • Covid-19 impact and recovery analysis
              • Data on revenue-generating market segments
              • Details on the market shares of various regions
              • Five-force market analysis